ImmunoGen (IMGN) : During the past 4 weeks, traders have been relatively bearish on ImmunoGen (IMGN), hence the stock is down -20.35% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -15.02% relative to the S&P 500. The 4-week change in the price of the stock is -16.87% and the stock has fallen -13.75% in the past 1 week. The stock has recorded a 20-day Moving Average of 12.05% and the 50-Day Moving Average is 39.32%.
ImmunoGen (NASDAQ:IMGN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.76 and $2.68 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.82. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.76, notching a gain of 0.73% for the day. The total traded volume was 1,314,148 . The stock had closed at $2.74 on the previous day.
The company Insiders own 4.2% of ImmunoGen shares according to the proxy statements. Institutional Investors own 86.79% of ImmunoGen shares. In a related news,The officer (Executive Vice President) of Immunogen Inc, Lambert John sold 3,889 shares at $8.22 on February 1, 2016. The Insider selling transaction had a total value worth of $31,968. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.